Ingenious Med Competitors and Similar CompaniesClear all

Ingenious Med's competitors and similar companies include Change Healthcare, Evolent Health and Sermo.

	Ingenious Med The premiere patient encounter platform, unifying communication, coding, revenue, and business intelligence into a single easily integrated solution.	Change Healthcare Change Healthcare is a provider of data and analytics-driven solutions for clinical, financial, administrative, and patient engagement.	Evolent Health Evolent Health is a company developing a health management platform.	Sermo Sermo is an online physicians-only community collaborating on difficult cases and exchanging observations about drugs and devices.
Founding Date	Founding Date 1999	Founding Date 2007	Founding Date 2011	Founding Date 2005
Type	Type Subsidiary	Type Subsidiary	Type Public	Type Private
Tags	Tags Healthcare platform	Tags Technology artificial intelligence automation data management healthtech machine learning platform	Tags Healthcare healthtech hospitals performance management systems integrator	Tags Healthcare platform
Locations	Locations Atlanta, US HQ	Locations Eden Prairie, US HQ Dublin, IE Marlow, GB Alpharetta, US	Locations Arlington, US HQ Arlington, US Chicago, US	Locations New York, US HQ Toronto, CA Dalian, CN Hamburg, DE Minato, JP Vilnius, LT Heroica Puebla De Zaragoza, MX see more
Employees	Employees 105	Employees 4,6352% decrease	Employees 4,7008% decrease	Employees 629
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $3.5b (FY, 2022)	Revenue (est.) $1.9b (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods $1.4b (FY, 2022)	Cost of goods $1.5b (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit $2.1b (FY, 2022)	Gross profit $399.9m (FY, 2025)	Gross profit N/A
Net income	Net income N/A	Net income ($57.4m) (FY, 2022)	Net income ($579.4m) (FY, 2025)	Net income N/A
Funding
Total funding raised	Total funding raised $ 3.3m	Total funding raised $ 48m	Total funding raised $ 267m	Total funding raised $ 60m